Improving Off-Label Policy Through The Lens of Trazodone Usage And Spending in The U.S.

Join us on Wednesday, August 13, as researchers share findings from their study and discuss policy solutions. In a new study published in Health Affairs Scholar, UCLA Center for Health Policy Research Senior Economist Dr. Srikanth Kadiyala, and co-authors look at the uses of trazodone, a drug approved in 1981 to treat depression, as a case study to examine broader issues surrounding off-label use and spending. Although only approved to treat depression, trazodone is often prescribed off-label to treat insomnia and anxiety.